Skip to search formSkip to main contentSkip to account menu

Vidaza

Known as: Pharmion Brand of Azacitidine 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Azacitidine
Azacitidine 100 MG Injection [Vidaza]Azacitidine Injection [Vidaza]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
PP-012 Conserving cold chain compliance in the reconstitution of vidaza in isolators
Background Vidaza (azacitidine), comes in vials of sterile lyophilised powder for reconstitution with water for injections in a… 
2013
2013
Abstract 683: Toxicity of aerosolized azacytidine (Vidaza) in mice.
Background: Azacytidine, a prototypical demethylation agent, has been approved to treat myelodysplastic syndrome. Commercial… 
2012
2012
Maintenance of an unbroken cold chain throughout the preparation of azacitidine (Vidaza) injection syringes.
Background Azacitidine (Vidaza) is a powder to be made up into a suspension for injection whose stability, after reconstitution… 
Review
2012
Review
2012
[Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
2010
2010
Abstract 5024: Sorafenib in combination with modifiers of epigenetic mechanism induce synergistic cytotoxicity in human liver cancer cell lines
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Background: Hepatocellular carcinoma (HCC) is the… 
Review
2007
Review
2007
[Multiple myeloma].
Multiple myeloma is the second most common hematological malignancy. It is defined by the presence of monoclonal plasma cells… 
Review
2007
Review
2007
Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
MethylGene Inc, in collaboration with Pharmion Corp, is developing the small-molecule, isoform-selective compound MGCD-0103 in… 
2006
2006
Low dose Vidaza and thalidomide is an effective combination for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
6570 Vidaza and thalidomide were administered to 29 patients with MDS or AML. Vidaza was given at a dose of 75mg/kg subq × 5 days… 
2005
2005
Azacitine (vidaza) for myelodysplastic syndrome.
Azacitidine is a new drug with a novel mechanism of action; it can correct abberant gene expression in patients with… 
Review
2004
Review
2004
Methyltransferase inhibitors: changing the treatment algorithm for myelodysplastic syndromes.
An updated algorithm for management of myelodysplastic syndromes incorporates newer effective treatment options. 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)